

Pubblicazioni:

Circulating miR-375 as a novel prognostic marker for metastatic medullary thyroid cancer patients

Romeo P, Colombo C, Granata R, Calareso G, Gualeni AV, Dugo M, De Cecco L, Rizzetti MG, Zanframundo A, Aiello A, Carcangiu ML, Gloghini A, Ferrero S, Licitra L, Greco A, Fugazzola L, **Locati** LD, Borrello MG.
Endocr Relat Cancer. 2018 Jan 3. pii: ERC-17-0389. doi: 10.1530/ERC-17-0389.

Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?

Bossi P, Siano M, Bergamini C, Cossu Rocca M, Sponghini AP, Giannoccaro M, Tonella L, Paoli A, Marchesi E, Perrone F, Pilotti S, **Locati** LD, Canevari S, Licitra L, De Cecco L.
Dis Markers. 2017;2017:6870614. doi: 10.1155/2017/6870614. Epub 2017 Nov 12.

Retreatment with Vismodegib after Progression in Advanced Basal Cell Carcinoma: First-Time Report of a Single-Institution Experience.

Alfieri S, Bergamini C, Granata R, **Locati** L, Licitra L, Bossi P.
Target Oncol. 2017 Dec 12. doi: 10.1007/s11523-017-0545-y.

RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?

Resteghini C, Alfieri S, Quattrone P, Dominoni F, Garzone G, Orlandi E, Locati L, Bergamini C, Galbiati D, Iacovelli NA, Fallai C, Licitra L, Bossi P.
Oncotarget. 2017 Oct 16;8(56):96184-96189. doi: 10.18632/oncotarget.21856. eCollection 2017 Nov 10.

In situ hybridization detection methods for HPV16 E6/E7 mRNA in identifying transcriptionally active HPV infection of oropharyngeal carcinoma: an updating.

Volpi CC, Ciniselli CM, Gualeni AV, Plebani M, Alfieri S, Verderio P, **Locati** L, Perrone F, Quattrone P, Carbone A, Pilotti S, Gloghini A
Hum Pathol. 2017 Oct 6. pii: S0046-8177(17)30356-8. doi: 10.1016/j.humpath.2017.09.011

A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Bossi P, Miceli R, **Locati** LD, Ferrari D, Vecchio S, Moretti G, Denaro N, Caponigro F, Airoidi M, Moro C, Vaccher E, Sponghini A, Caldara A, Rinaldi G, Ferrau F, Nolè F, Lo Vullo S, Tettamanzi F, Hollander L, Licitra L.
Ann Oncol. 2017 Nov 1;28(11):2820-2826. doi: 10.1093/annonc/mdx439.

Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.

Resteghini C, Cavalieri S, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, **Locati**LD.
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):349-361. doi: 10.1016/j.beem.2017.04.012.

Do not throw the baby out with the bathwater: SELECT a personalized, de-escalated lenvatinib schedule allows response in locally advanced DTC while controlling major drug-related bleeding.

Resteghini C, **Locati** LD, Bossi P, Bergamini C, Guzzo M, Licitra L.
Ann Oncol. 2017 Sep 1;28(9):2321-2322. doi: 10.1093/annonc/mdx251.

Circulating pre-treatment Epstein-Barr virus DNA as prognostic factor in locally-advanced nasopharyngeal cancer in a non-endemic area.

Alfieri S, Iacovelli NA, Marceglia S, Lasorsa I, Resteghini C, Taverna F, Mazzocchi A, Orlandi E, Guzzo M, Bianchi R, Fanti D, Pala L, Racca S, Dvir R, Quattrone P, Gloghini A, Volpi CC, Granata R, Bergamini C, **Locati** L, Licitra L, Bossi P.
Oncotarget. 2017 Jul 18;8(29):47780-47789. doi: 10.18632/oncotarget.17822.

Outcome of recurrent and metastatic head and neck squamous cell cancer patients after first line platinum and cetuximab therapy.

Siano M, Infante G, Resteghini C, Cau MC, Alfieri S, Bergamini C, Granata R, Miceli R, **Locati** L, Licitra L, Bossi P.
Oral Oncol. 2017 Jun;69:33-37. doi: 10.1016/j.oraloncology.2017.04.002.

Lung metastasectomy in adenoid cystic cancer: Is it worth it?

Girelli L, **Locati** L, Galeone C, Scanagatta P, Duranti L, Licitra L, Pastorino U.
Oral Oncol. 2017 Feb;65:114-118. doi: 10.1016/j.oraloncology.2016.10.018. Epub 2016 Oct 26.

Systemic therapy in metastatic salivary gland carcinomas: A pathology-driven paradigm?

Alfieri S, Granata R, Bergamini C, Resteghini C, Bossi P, Licitra LF, **Locati** LD.
Oral Oncol. 2017 Mar;66:58-63. doi: 10.1016/j.oraloncology.2016.12.016. Epub 2017

The EORTC module for quality of life in patients with thyroid cancer: phase III.

Singer S, Jordan S, **Locati LD**, Pinto M, et al.
Endocr Relat Cancer. 2017 Feb 21 [Epub ahead of print]

Immunohistochemical and molecular profile of salivary gland cancer in children.

Locati LD, Collini P, Imbimbo M, Barisella M, Testi A, Licitra LF, et al.
Pediatr Blood Cancer. 2017 Jan 31. [Epub ahead of print]

Integrative miRNA-Gene Expression Analysis Enables Refinement of Associated Biology and Prediction of Response to Cetuximab in Head and Neck Squamous Cell Cancer.

De Cecco L, Giannoccaro M, Marchesi E, Bossi P, Favales F, **Locati LD**, et al.
Genes (Basel). 2017; 14:8(1).

Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer.

Bastholt L, Kreissl MC, Führer D, Maia AL, **Locati LD**, et al.
Eur Thyroid J. 2016; 5(3):187-194

A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact.

Locati LD, Perrone F, Cortelazzi B, Bergamini C, Bossi P, et al.
Eur J Cancer. 2016; 69:158-165

Quality-of-Life Priorities in Patients with Thyroid Cancer: A Multinational European Organisation for Research and Treatment of Cancer Phase I Study.

Singer S, Husson O, Tomaszewska IM, **Locati LD**, et al.
Thyroid. 2016;26(11):1605-1613.

Safety of combination treatment with imatinib mesylate, carboplatin, and cetuximab in a patient with multiple cancers: a case report.

Pala L, Bergamini C, Imbimbo M, Granata R, **Locati L**, et al.
Tumori. 2016; 11;102(Suppl. 2).

Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy.

Bossi P, Bergamini C, Miceli R, Cova A, Orlandi E, Resteghini C, **Locati L**, et al.
Int J Radiat Oncol Biol Phys. 2016; 1;96(5):959-966.

Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab

Bossi P, Bergamini C, Siano M, Cossu Rocca M, Sponghini AP, Favales F, Giannoccaro M, Marchesi E, Cortelazzi B, Perrone F, Pilotti S, **Locati LD** et al. .
Clin Cancer Res. 2016;22(15):3961-70

Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer.

Alfieri S, Ripamonti CI, Marcegaglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, **Locati LD** et al.
Head Neck. 2016 ;38 Suppl 1:E1521-7

Does a multidisciplinary team approach in a tertiary referral centre impact on the initial management of head and neck cancer?

Bergamini C, **Locati L**, Bossi P et al
Oral Oncol. 2016 Mar;54:54-7

Health care-associated infections in patients with head and neck cancer treated with chemotherapy and/or radiotherapy.

Mirabile A, Vismara C, Crippa F, Bossi P, **Locati L** et al
Head Neck. 2016 Apr;38 Suppl 1:E1009-13

Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data.

De Cecco L, Nicolau M, Giannoccaro M, Daidone MG, Bossi P, **Locati L**, et al.
Oncotarget. 2015 Apr 20;6(11):9627-42.

Genetic profiling of advanced radioactive iodine-resistant differentiated thyroid cancer and correlation with axitinib efficacy.

Schechter RB, Nagilla M, Joseph L, Reddy P, Khattri A, Watson S, **Locati LD** et al.
Cancer Lett. 2015 Apr 10;359(2):269-74.

Receptor tyrosine kinase profiles and human papillomavirus status in oropharyngeal squamous cell carcinoma.

Cortelazzi B, Verderio P, Ciniselli CM, Pizzamiglio S, Bossi P, Gloghini A, Gualeni AV, Volpi CC, **Locati L**, et al.
J Oral Pathol Med. 2014 Dec 14. [Epub ahead of print]

Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review.

Orlandi E, Takanen S, Giandini T, Iannacone E, Fontanella W, **Locati L**, Carrara M, Bossi P, Bergamini C, Granata R, Tombolini V, Ibbi T, Licitra L, Pignoli E, Fallai C.
Future Oncol. 2014 Nov;10(14):2111-20

Oral prevalence and clearance of oncogenic human papilloma virus (HPV) in a rehabilitation community for substance abusers in Italy: a case of behavioral correction?

Pugliese B, Davide, Bruzzesi Giacomo, Montaldo Caterina, Porcu Luca, Landi Marco, Mastinu Andrea, Torri Valter, Licitra Lisa*, **Locati D. Laura***
J Oral Pathol Med. 2014 Nov 17

Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed AR-positive salivary gland cancers

Locati LD, Federica Perrone; Barbara Cortelazzi et al.
Head Neck. 2014 Dec 18. [Epub ahead of print]

Fosbretabulin for the treatment of anaplastic thyroid cancer.

Granata R, **Locati LD**, Licitra L.
Future Oncol. 2014 Oct;10(13):2015-21.

Occupation and cancer of the larynx: a systematic review and meta-analysis.

Bayer O, Cámara R, Zeissig SR, Rensing M, Dietz A, **Locati LD** et al.
Eur Arch Otorhinolaryngol. 2014 Oct 14. [Epub ahead of print]

Antiangiogenic TKIs and advanced RAI-resistant thyroid cancer: time for treatment strategy rethinking?

Licitra L, **Locati L**.
Thyroid. 2014 Sep 2. [Epub ahead of print]

Fentanyl pectin nasal spray as treatment for incident predictable breakthrough pain (BTP) in oral mucositis induced by chemoradiotherapy in head and neck cancer.

Bossi P, **Locati L**, Bergamini C et al.
Oral Oncol. 2014 Sep;50(9):884-7

Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.

Locati LD, Licitra L, Agate L et al.
Cancer. 2014 Sep 1;120(17):2694-703

Comprehensive gene expression meta-analysis of head and neck squamous cell carcinoma microarray data defines a robust survival predictor.

De Cecco L, Bossi P, **Locati L** et al.
Ann Oncol. 2014 Aug;25(8):1628-35

Activity of abiraterone in rechallenging two AR-expressing salivary gland adenocarcinomas, resistant to androgen-deprivation therapy.

Locati LD, Perrone F, Cortelazzi B et al.
Cancer Biol Ther. 2014 Jun 1;15(6):678-82

Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis.

Bossi P, Orlandi E, Miceli R, Perrone F, Guzzo M, Mariani L, Granata R, **Locati L** et al.
Ann Oncol. 2014 Mar;25(3):694-9

Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial.

Bossi P, Lo Vullo S, Guzzo M, Mariani L, Granata R, Orlandi E, **Locati L** et al.
Ann Oncol. 2014 Feb;25(2):462-6

Emerging tyrosine kinase inhibitors for head and neck cancer.

Bossi P, **Locati L**, Licitra L
Expert Opin Emerg Drugs. 2013 Dec;18(4):445-59

Salivary gland cancer: an update on present and emerging therapies.

Carlson J, Licitra L, **Locati L** et al.
Am Soc Clin Oncol Educ Book. 2013:257-63

Therapeutic strategies in the management of patients with metastatic anaplastic thyroid cancer: review of the current literature.

Granata R, **Locati L**, Licitra L.
Curr Opin Oncol. 2013 May;25(3):224-8

RET inhibition: implications in cancer therapy.

Borrello MG, Ardini E, **Locati LD**, Greco A, Licitra L, Pierotti MA.
Expert Opin Ther Targets. 2013 Apr;17(4):403-19

Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma.

Bossi P, Perrone F, Miceli R, Cantù G, Mariani L, Orlandi E, Fallai C, **Locati LD**, Cortelazzi B, Quattrone P, Potepan P, Licitra L, Pilotti S.
Oral Oncol. 2013 May;49(5):413-9

Critical analysis of locoregional failures following intensity-modulated radiotherapy for nasopharyngeal carcinoma.

Orlandi E, Tomatis S, Potepan P, Bossi P, Mongioj V, Carrara M, Palazzi M, Franceschini M, Bergamini C, **Locati L**, Iannacone E, Guzzo M, Ibba T, Crippa F, Licitra L, Pignoli E, Fallai C.
Future Oncol. 2013 Jan;9(1):103-14

Management of salivary gland tumors.

Andry G, Hamoir M, **Locati LD**, Licitra L, Langendijk JA.
Expert Rev Anticancer Ther. 2012 Sep;12(9):1161-8.

Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.

Bossi P, Resteghini C, Perrone F, Cortelazzi B, Pilotti S, Maurichi A, **Locati LD**, Licitra L.
J Am Acad Dermatol. 2012 Nov;67(5):e226-8

Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer.

Bossi P, Kornek G, Lanzetta G, Rozzi A, Füreder T, **Locati L**, Licitra L.
Head Neck. 2012

Multikinase inhibitors in thyroid cancer.

Licitra L, **Locati LD**.
Ann Oncol. 2012 Sep;23 Suppl 10:x328-33

How Many Therapeutic Options Are There for Recurrent or Metastatic Salivary Duct Carcinoma?

Locati LD, Bossi P, Licitra L.
J Clin Oncol. 2012 Jan 17.

Palifermin in prevention of head and neck cancer radiation-induced mucositis: not yet a definitive word on safety and efficacy profile.

Bossi P, **Locati LD**, Licitra L. J Clin Oncol. 2012 Feb 10;30(5):564-5.

Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study.

Granata R, Miceli R, Orlandi E, Perrone F, Cortelazzi B, Franceschini M, **Locati LD** et al.
Ann Oncol. 2011 Dec 21. [Epub ahead of print]

T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.

Secondino S, Zecca M, Licitra L, Gurrado A, Schiavetto I, Bossi P, **Locati L**, et al.
Ann Oncol. 2012 Feb;23(2):435-41.

“Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients”

Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, Bossi P, **Locati LD** et al.
Ann Oncol. 2011;22(8):1886-93

Comment on "Acute toxicity of three versus two courses of cisplatin for radiochemotherapy of locally advanced squamous cell carcinoma of the head and neck (SCCHN): a matched pair analysis", by Rades et coll.

Bossi P, Granata R, Bergamini C, Mirabile A, **Locati L**, Licitra L.
Oral Oncol. 2010;46(12):888; author reply 889-90

“Multikinase inhibitors in thyroid cancer”

Licitra L, **Locati LD**, Greco A et al.
Eur J Cancer. 2010 Apr;46(6):1012-8

“TP53 Mutations and Pathologic Complete Response to Neoadjuvant Cisplatin and Fluorouracil Chemotherapy in Resected Oral Cavity Squamous Cell Carcinoma.”

Perrone F, Bossi P, Cortelazzi B, **Locati L**, et al.
J Clin Oncol. 2010 Feb 10;28(5):761-6

“Major and minor salivary gland tumors.”

Guzzo M, **Locati LD**, Prott FJ, et al.
Crit Rev Oncol Hematol. 2010 May;74(2):134-48

“Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.”

Fallai C, Perrone F, Licitra L, Pilotti S, **Locati L**, et al.
Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1053-9.

“Treatment relevant target immunophenotyping of 139 salivary gland carcinomas (SGCs).”

Locati LD, Perrone F, Losa M et al
Oral Oncol. 2009 Nov;45(11):986-90.

“Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.”

Schlumberger MJ, Elisei R, Bastholt L, Wirth LJ, Martins RG, **Locati LD**, et al.
J Clin Oncol. 2009 Aug 10;27(23):3794-801.

“High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: Results of a survey in EORTC institutes.”

Giro C, Berger B, Bölke E, Ciernik IF, Duprez F, **Locati L**, et al.
Radiother Oncol. 2009 Feb;90(2):166-71.

“Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).

”van Herpen CM, **Locati LD**, Buter J, Thomas J, Bogaerts J, Lacombe D, de Mulder P, Awada A, Licitra L, Bernier J, Vermorken JB.
Eur J Cancer. 2008 Nov;44(17):2542-5.

“Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.”

Locati LD, Bossi P, Perrone F, et al.
Oral Oncol. 2008 Sep 17.

“Optimizing approaches to head and neck cancer. Metastatic head and neck cancer: new options.”

Licitra L, **Locati LD**, Bossi P.
Ann Oncol. 2008 Sep;19 Suppl 7:vii200-3. Review.

“TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma”.

Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, **Locati LD**, et al.
Transl Oncol. 2008 Sep;1(3):121-8.

“Folate in head and neck squamous cell cancer chemoprevention: purposely left out?”

Bossi P, **Locati LD**, Licitra L, Tagliabue E.
J Clin Oncol. 2008 Jul 10;26(20):3463; author reply 3463-4

“Biological agents in head and neck cancer.”

Bossi P, **Locati LD**, Licitra L.
Expert Rev Anticancer Ther. 2007 Nov;7(11):1643-50. Review.

“Advances in the changing patterns of aetiology of head and neck cancers”

Licitra L, Rossini C, Bossi P, **Locati LD**
Curr Opin Otolaryngol Head Neck Surg. 2006 Apr;14(2):95-9.

“High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma”

Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, **Locati LD**, et al.
JCO Dec 20 2006: 5630–5636

“Molecular and cytogenetic subgroups of oropharyngeal squamous cell carcinoma”.

Perrone F, Suardi S, Pastore E, Casieri P, Orsenigo M, Caramuta S, Dagrada G, Losa M, Licitra L, Bossi P, Staurengo S, Oggionni M, **Locati L** et al.
Clin Cancer Res. 2006 Nov 15;12(22):6643-51.

“Previously irradiated areas spared from skin toxicity induced by cetuximab in six patients: implications for the administration of EGFR inhibitors in previously irradiated patients”

Bossi P, Liberatoscioli C, Bergamini C, **Locati L**, et al.
Ann Oncol. 2006 Oct 30

“Biological agents in head and neck cancer”.

Licitra L, **Locati L**, Bossi P.
Ann Oncol. 2006 Sep;17 Suppl 10:x45-x48.

“A multidisciplinary approach to squamous cell carcinomas of the head and neck: what is new?”

Licitra L, Bossi P, **Locati LD**.
Curr Opin Oncol. 2006 May;18(3):253-7.

Is restoring platinum sensitivity the best goal for cetuximab in recurrent/metastatic nasopharyngeal cancer?

Licitra L, Bossi P, **Locati LD**, Bergamini C.
J Clin Oncol, 2005; 23(30): 7757-8

“Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary gland”

Locati LD, Guzzo M, Bossi B et al.
Oral Oncol. 2005; 41(9):890-4.

“Prediction of TP53 status for primary PFL chemotherapy in ethmoid sinus intestinal –type adenocarcinoma”

Licitra L, Suardi S, Bossi P, **Locati L** et al.
J Clin Oncol. 2004 Dec 15;22(24):4901-6

“Which classification for ethmoid malignant tumours involving the anterior skull base?”

Cantù G, Solero CL, Miceli R, Mariani L, Mattavelli F, Squadrelli Saraceno M, Bimbi G, Riccio S, Colombo S, **Locati L**, et al.
Head Neck, 2005; 27: 224-231

“Herceptin plus chemotherapy in relapsed and/or metastatic salivary gland cancer”

Locati LD, Rinaldi G, Bossi P, Dagrada GP, Quattrone P, Cantù G, Licitra L.
Oral Oncol 2005 Jan;41(1):97-8.

“Head and Neck Cancer”

Licitra L, Locati LD, Bossi P.
Ann Oncol, 2004; 15 (s4): iv267-iv273

“Regionally advanced nasopharyngeal carcinoma: long-term outcome after sequential chemotherapy and radiotherapy”

M. Palazzi, M. Guzzo, P. Bossi, S. Tomatis, A. Corrotta, G. Cantù, LD Locati, L. Licitra
Tumori, 2004; 90 (1): 60-65

“Head and neck tumors other than squamous cell carcinomas”

Lisa Licitra, Laura D. Locati, Paolo Bossi, Giulio Cantù
Curr Opin Oncol, 2004 May; 16(3): 236-41

“Cisplatin and fluorouracil concurrent to radiotherapy in nasopharyngeal cancer: is the schedule compatible?”

Licitra L, Bossi P, Locati L, Zunino F.
J Clin Oncol, 2004; 22 (2): 377

“Cancer of larynx”.

L. Licitra, J. Bernier, C. Grandi, L. Locati, et al.
Critical Reviews in Oncology/Hematology. 2003; 47: 65-80

“A complete remission with androgen deprivation therapy in a recurrent androgen receptors expressing adenocarcinoma of the parotid gland”.

Locati LD, Quattrone P, Bossi P et al.
Ann Oncol. 2003; 14 (8): 1327-8.

“Primary chemotherapy followed by anterior craniofacial resection and radiotherapy for paranasal cancer”

L. Licitra, L. D. Locati, R. Cavina et al.
Ann Oncol, 2003; 14 (3): 367-372.

“Primary high-grade mucoepidermoid carcinoma of the minor salivary glands with cutaneous metastases at diagnosis: report of a case and review of the literature”

LD Locati, P. Quattrone, N. Pizzi, et al.
Oral Oncology, 2002; 38: 401-404

“Clozapine and full dose concomitant chemo-radiation therapy in a schizophrenic patient with nasopharyngeal cancer”

C. Bareggi, M. Palazzi, L. D. Locati, et al.;
Tumori, 2002; 88 (1): 59-60

“Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma”

G. L. Ceresoli, LD Locati, A. J. M. Ferreri, et al.
Lung Cancer, 2001; 34: 279-287